2008至2019年65个国家/地区直接口服抗凝药消费趋势演变
该生态学研究利用IQVIA-MIDAS数据库药品销售数据,估算2008至2019年65个国家/地区四种DOAC的消费量(DDDTID)与成本。结果显示全球消费模式存在区域差异,利伐沙班和阿哌沙班在多数国家消费量超过达比加群,依度沙班除东亚外使用有限,美国支付价格更高。
要点
- 2019年Q2全球消费量:阿哌沙班1.08、利伐沙班1.05、依度沙班0.78、达比加群0.31 DDDTID。
- 西欧、北欧和大洋洲消费量最高(18.2、14.07、13.14 DDDTID)。
- 46/65国(70%)利伐沙班占DOAC消费主体(35%-100%),达比加群不足三分之一。
核心结论
- 过去十年DOAC消费模式与趋势存在区域差异。
- 利伐沙班和阿哌沙班在多数国家消费量超过达比加群。
- 依度沙班使用除东亚国家外仍有限。
- 美国DOAC价格高于其他国家。
研究设计与样本
- 生态学研究,使用IQVIA-MIDAS数据库药品销售数据。
- 覆盖2008至2019年65个国家/地区。
- 消费量以defined-daily-dose/1000-inhabitants/day(DDDTID)表示。
- 成本以每治疗日制造商价格估算。
主要发现
- 2019年Q2全球消费量:达比加群0.31、利伐沙班1.05、阿哌沙班1.08、依度沙班0.78 DDDTID。
- 2015年Q2对应消费量:达比加群0.23、利伐沙班0.54、阿哌沙班0.21、依度沙班0.03 DDDTID。
- 消费量最高地区:西欧18.2、北欧14.07、大洋洲13.14 DDDTID。
- 46/65国(70%)利伐沙班占DOAC消费35%-100%,达比加群不足三分之一。
- 依度沙班在北美和欧洲占比<20%,但在日本占28.58%、韩国占31.37%。
临床怎么用
- 了解区域DOAC消费模式差异,辅助药品选择与预算规划。
- 关注利伐沙班和阿哌沙班在多数国家消费量超过达比加群的趋势。
- 东亚地区依度沙班使用比例显著高于欧美。
- 美国DOAC价格较高,需考虑成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Direct oral anticoagulants (DOACs) have been increasingly utilised over warfarin. However, little is known about the relative consumption trends and costs of each DOAC at the global level. METHODS: An ecological study using pharmaceutical sales data from IQVIA-MIDAS database was used to estimate consumption and cost of individual DOACs in 65 countries from 2008 to 2019. Consumption was estimated from the volume of DOACs sold, expressed as defined-daily-dose/1000-inhabitants/day (DDDTID). Compound and absolute annual growth rates were reported to quantify consumption changes over time. Costs were estimated as manufacturer price per day-of-therapy. RESULTS: Global consumption of dabigatran, rivaroxaban, apixaban and edoxaban were 0.31, 1.05, 1.08 and 0.78 DDDTID, respectively, in Q2-2019, compared to 0.23, 0.54, 0.21 and 0.03 in Q2-2015, with highest consumption in Western Europe, Northern Europe and Oceania (18.2, 14.07, 13.14 DDDTID). In most countries (46/65, 70%), rivaroxaban contributed to most DOAC consumption (35%-100%), whereas dabigatran accounted for less than one-third. Edoxaban accounted for < 20% of the total in Northern America and Europe but contributed significant proportions in Japan (28.58%) and South Korea (31.37%). Longer median time-to-adoption from FDA approval for apixaban and edoxaban was observed. Costs of all DOACs were ~2-4 times higher in the USA, Puerto Rico and Thailand than in other countries. CONCLUSIONS: Regional differences exist in consumption pattern and trends of individual DOACs over the past decade. Consumption of rivaroxaban and apixaban overtook dabigatran in most countries, whereas use of edoxaban remains limited except in East Asian countries. The USA pays higher prices for DOACs than other countries.
引用
- Yan VKC, Li HL, Wei L, et al. Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019. Drugs. 2023. PMID: 36840892. doi:10.1007/s40265-023-01837-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。